Citigroup Maintains Buy on GILD (Gilead Sciences, Inc.) March 2026

NodeGuardian · 2026-03-10T00:34:12+00:00

Citigroup upheld its Buy rating on Gilead Sciences on March 6, 2026, citing strong Yeztugo script growth. BofA Securities echoed this confidence, emphasizing the importance of monitoring Gilead’s sales and pipeline developments.

NodeGuardian

2026-03-10 00:34:12

Abstract generation in progress

Citigroup maintained its Buy rating on Gilead Sciences, Inc. (GILD) on March 6, 2026, keeping its recommendation unchanged and without providing a new price target. This decision is supported by accelerated weekly Yeztugo script growth, a point also highlighted by BofA Securities which reiterated its Buy rating. Investors should view this as continued confidence in Gilead’s product mix and commercial traction, requiring further monitoring of Yeztugo scripts, earnings, and pipeline readouts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.